Deals and Financings
HitGen, a Chengdu small molecule discovery company, has been approved for a $97 million IPO on Shanghai's new Science and Technology Innovation Board. HitGen has built a DNA-encoded library that contains nearly 400 billion novel, diverse, drug-like small molecule and macrocyclic compounds. The company is a partnering wonder, having formed more than 60 drug discovery partnerships with a collection of well-known China and global pharmas, including big pharma companies. It has also developed its own portfolio of 20 candidates for various cancer, cardiovascular, inflammatory and metabolic indications.
Shenzhen Chipscreen Biosciences is expected